Sino Biopharmaceutical Ltd

Company Profile

• Business description

  Listed on the Hong Kong Stock Exchange in 2000, Sino Biopharmaceutical is one of the largest Chinese drugmakers. It has four main segments: oncology, liver, surgery/analgesics, and autoimmune/respiratory. Since 2018, Sino Biopharm has been actively pivoting into an innovative drugmaker for oncology after the Chinese government launched its volume-based procurement policy for the healthcare industry, whereby it reduces the price of its generic drugs in exchange for bulk procurement of its products. Oncology drugs make up its core innovative portfolio, while the other drugs are considered generic, which currently make up about half of its total revenue. Sino Biopharm competes with Hutchmed and Hengrui in the domestic oncology market, while it has a minimal presence in the global market.

• Contact

  1 Harbour Road
  Unit 09, 41st Floor, Office Tower, Room 4109
  Convention Plaza
  Wanchai
  Hong Kong
  HKG

  T: +852 28029886

  https://www.sbpgroup.com

• Sector

  Healthcare

  Stock type

  Defensive

• Industry

  Biotechnology

  Fiscal Year End

  31 December 2026

  Employees

  21,435